Last reviewed · How we verify
CD73 Antigen
At a glance
| Generic name | CD73 Antigen |
|---|---|
| Also known as | PM1015 injection |
| Sponsor | Biotheus Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of PM1015 in Patients With Advanced Solid Tumors (PHASE1)
- IMPase in Treatment-resistant Depression (PHASE1)
- Ebselen as an add-on Treatment in Hypo/Mania (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD73 Antigen CI brief — competitive landscape report
- CD73 Antigen updates RSS · CI watch RSS
- Biotheus Inc. portfolio CI